LFCR
NASDAQ · Life Sciences Tools & Services
Lifecore Biomedical Inc
$5.09
-0.18 (-3.42%)
Financial Highlights (FY 2026)
Revenue
73.08M
Net Income
-17,378,321
Gross Margin
31.4%
Profit Margin
-23.8%
Rev Growth
-9.9%
D/E Ratio
4.18
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 31.4% | 31.4% | 44.5% | 44.5% |
| Operating Margin | -1.0% | -0.9% | 6.5% | 6.6% |
| Profit Margin | -23.8% | -22.6% | 5.3% | 5.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 73.08M | 81.11M | 344.67M | 265.26M |
| Gross Profit | 22.92M | 25.45M | 153.43M | 118.09M |
| Operating Income | -708,827 | -708,118 | 22.32M | 17.47M |
| Net Income | -17,378,321 | -17,360,960 | 18.11M | 14.22M |
| Gross Margin | 31.4% | 31.4% | 44.5% | 44.5% |
| Operating Margin | -1.0% | -0.9% | 6.5% | 6.6% |
| Profit Margin | -23.8% | -22.6% | 5.3% | 5.4% |
| Rev Growth | -9.9% | -9.9% | +6.7% | +0.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 77.02M | 77.02M | 31.30M | 33.69M |
| Total Equity | 18.44M | 18.44M | 172.81M | 150.13M |
| D/E Ratio | 4.18 | 4.18 | 0.18 | 0.22 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 4.65M | 4.91M | 26.32M | 22.29M |
| Free Cash Flow | — | — | 8.29M | 10.33M |